Two new precision medicine tests that look beyond cancer genes to identify novel therapeutic targets are now available to both oncologists and cancer researchers.
A Super Bowl ad has launched a new campaign at NewYork-Presbyterian Hospital that showcases Columbia and Weill Cornell expertise in cancer, particularly immunotherapy.
A comprehensive analysis of the molecular characteristics of gliomas—the most common malignant brain tumor—explains why some patients diagnosed with slow-growing (low-grade) tumors quickly succumb to the disease while others with more aggressive (high-grade) tumors survive for many years.
NewYork-Presbyterian, Columbia University Medical Center and Weill Cornell Medicine are among the nation’s top cancer centers calling for increased human papillomavirus (HPV) vaccination for the prevention of cancer.
Researchers have identified a biomarker that predicts which stage II colon cancer patients may benefit from adjuvant chemotherapy to prevent a disease recurrence.
A new targeted therapy for hard-to-treat chronic lymphocytic leukemia appears to have fewer side effects than a previous therapy.